Abstract
Sudden cardiac death (SCD) is the most devastating complication of hypertrophic cardiomyopathy (HCM). The greatest challenge in the management of HCM is identifying those at increased risk, since an implantable cardioverter-defibrillator (ICD) is a potentially life-saving therapy. We sought to summarize the available data on SCD in HCM and provide a clinical perspective on the current differing and somewhat conflicting data on risk stratification, with balanced guidance regarding rational clinical decision-making. Additionally, we sought to determine the status of the current implementation of guidelines compiled by HCM experts worldwide. The HCM Risk-SCD model helps improve the risk stratification of HCM patients for primary prevention of SCD by calculating an individual risk estimate that contributes to the clinical decision-making process. Improved risk stratification is important for decision-making before ICD implantation for the primary prevention of SCD.
Zusammenfassung
Der plötzliche Herztod („sudden cardiac death“, SCD) stellt die schwerwiegendste Komplikation der hypertrophen Kardiomyopathie (HCM) dar. Die größte Herausforderung in der Behandlung der HCM ist es, gefährdete Patienten zu erkennen, denn ein implantierbarer Defibrillator („implantable cardiac defibrillator“, ICD) ist ein potenziell lebensrettender Therapieansatz. Ziel der Autoren war es, die verfügbaren Daten zum SCD bei HCM zusammenzufassen und die aktuellen unterschiedlichen und sich teils widersprechenden Daten zur Risikostratifizierung aus klinischer Sicht mit einer ausgewogenen Anleitung zur rationalen klinischen Entscheidungsfindung zu erörtern. Darüber hinaus war es das Ziel, den aktuellen Stand der Etablierung der durch HCM-Spezialisten erstellten Leitlinien zu bestimmen. Das HCM Risk-SCD Modell trägt dazu bei, die Risikostratifizierung von HCM-Patienten zur Primärprävention eines SCD durch Berechnung eines individuellen Risikoschätzwerts zu verbessern, welcher einen Beitrag zum klinischen Entscheidungsfindungsprozess leistet. Eine verbesserte Risikostratifizierung ist für die Entscheidungsfindung vor einer ICD-Implantation zur Primärprävention des SCD von großer Bedeutung.
Similar content being viewed by others
References
Maron BJ, Ommen SR, Semsarian C et al (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64(1):83–99
Maron BJ, Gardin JM, Flack JM et al (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92(4):785–789
Trivedi A, Knight BP (2016) ICD therapy for primary prevention in hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 5(3):188–196
Hardarson T, De la Calzada CS, Curiel R, Goodwin JF (1973) Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 2(7844):1462–1467
Maron BJ, Olivotto I, Spirito P et al (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102(8):858–864
van der Werf C, van Langen IM, Wilde AAM (2010) Sudden death in the young: what do we know about it and how to prevent? Circ Arrhythm Electrophysiol 3(1):96–104
Weissler-Snir A, Adler A, Williams L et al (2017) Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J 38(22):1728–1737
Rowin EJ, Maron MS (2016) The role of cardiac MRI in the diagnosis and risk stratification of hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 5(3):197–202
Maron BJ, Rowin EJ, Casey SA et al (2015) Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 65(18):1915–1928
Maron BJ, Spirito P, Shen WK et al (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298(4):405–412
Gersh BJ, Maron BJ, Bonow RO et al (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58(25):e212–260
Kawashiri M, Hayashi K, Konno T et al (2014) Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels 29(2):129–141
Konno T, Shimizu M, Ino H et al (2003) A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. J Am Coll Cardiol 41(5):781–786
Konno T, Chang S, Seidman JG, Seidman CE (2010) Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 25(3):205–209
Disertori M, Masè M, Ravelli F (2017) Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends Cardiovasc Med 27(5):363–372
Varnava AM, Elliott PM, Mahon N et al (2001) Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 88(3):275–279
Basso C, Thiene G, Corrado D et al (2000) Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31(8):988–998
Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495
Nguyen TP, Qu Z, Weiss JN (2014) Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol 70:83–91
Morita N, Mandel WJ, Kobayashi Y, Karagueuzian HS (2014) Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm 30(6):389–394
de Jong S, van Veen TAB, van Rijen HVM, de Bakker JMT (2011) Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 57(6):630–638
Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779
Maron BJ, McKenna WJ, Danielson GK et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42(9):1687–1713
Betensky BP, Dixit S (2014) Sudden cardiac death in patients with nonischemic cardiomyopathy. Indian Heart J 66:S35–45
Veselka J, Anavekar NS, Charron P (2017) Hypertrophic obstructive cardiomyopathy. Lancet 389(10075):1253–1267
Maron BJ, Haas TS, Shannon KM et al (2009) Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm 6(7):993–997
Elliott PM, Sharma S, Varnava A et al (1999) Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 33(6):1596–1601
Elliott PM, Poloniecki J, Dickie S et al (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36(7):2212–2218
Olivotto I, Maron MS, Adabag AS et al (2005) Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):480–487
Maron BJ, Roberts WC, Epstein SE (1982) Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 65(7):1388–1394
Maron BJ, Rowin EJ, Casey SA et al (2013) Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation 127(5):585–593
Monserrat L, Elliott PM, Gimeno JR et al (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42(5):873–879
Gimeno JR, Tomé-Esteban M, Lofiego C et al (2009) Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 30(21):2599–2605
Dimitrow PP, Chojnowska L, Rudzinski T et al (2010) Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. Eur Heart J 31(24):3084–3093
Adabag AS, Casey SA, Kuskowski MA et al (2005) Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 45(5):697–704
Spirito P, Rapezzi C, Autore C et al (1994) Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 90(6):2743–2747
Borggrefe M, Kuhn H, Königer HH et al (1983) Arrhythmias in hypertrophic obstructive and non-obstructive cardiomyopathy. Eur Heart J 4(Suppl F):245–251
Viswanathan K, Suszko AM, Das M et al (2016) Rapid device-detected nonsustained ventricular tachycardia in the risk stratification of hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 39(7):642–651
Francia P, Santini D, Musumeci B et al (2014) Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 25(11):1180–1187
Behr ER, Elliott P, McKenna WJ (2002) Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 6(4):482–486
Spirito P, Maron BJ (1990) Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 15(7):1521–1526
Spirito P, Bellone P, Harris KM et al (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342(24):1778–1785
Sorajja P, Nishimura RA, Ommen SR et al (2006) Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 19(6):788–795
Elliott P, Gimeno J, Tomé M, McKenna W (2006) Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J 27(24):3073 (author reply 3073–3074)
Christiaans I, van Engelen K, van Langen IM et al (2010) Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 12(3):313–321
Maki S, Ikeda H, Muro A et al (1998) Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 82(6):774–778
Bos JM, Maron BJ, Ackerman MJ et al (2010) Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 106(10):1481–1486
Spirito P, Autore C, Rapezzi C et al (2009) Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119(13):1703–1710
O’Mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35(30):2010–2020
Li PR, Li XL, Xu F et al (2016) Clinical characteristics and outcome of patients with dilated-hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 44(4):327–330
Minami Y, Haruki S, Yashiro B et al (2016) Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation. J Cardiol 68(6):478–484
Debonnaire P, Joyce E, Hiemstra Y et al (2017) Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol 10(2):e004052. https://doi.org/10.1161/CIRCEP.116.004052
Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348(4):295–303
McLeod CJ, Ommen SR, Ackerman MJ et al (2007) Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 28(21):2583–2588
Vriesendorp PA, Liebregts M, Steggerda RC et al (2014) Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2(6):630–636
Ball W, Ivanov J, Rakowski H et al (2011) Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol 58(22):2313–2321
Pozios I, Corona-Villalobos C, Sorensen LL et al (2015) Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy. Am J Cardiol 116(6):938–944
Frenneaux MP, Counihan PJ, Caforio AL et al (1990) Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82(6):1995–2002
Olivotto I, Maron BJ, Montereggi A et al (1999) Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 33(7):2044–2051
Ciampi Q, Betocchi S, Lombardi R et al (2002) Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol 40(2):278–284
Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ (1991) Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 84(2):686–696
Campbell R, Manyari DE, McKenna WJ, Frenneaux M (2003) What is the mechanism of abnormal blood pressure response on exercise in hypertrophic cardiomyopathy? J Am Coll Cardiol 41(11):2102
Sadoul N, Prasad K, Elliott PM et al (1997) Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96(9):2987–2991
Desai MY, Bhonsale A, Patel P et al (2014) Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. JACC Cardiovasc Imaging 7(1):26–36
Moravsky G, Ofek E, Rakowski H et al (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 6(5):587–596
Briasoulis A, Mallikethi-Reddy S, Palla M et al (2015) Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 101(17):1406–1411
Maron MS, Appelbaum E, Harrigan CJ et al (2008) Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 1(3):184–191
Moon JCC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43(12):2260–2264
van der Bijl P, Delgado V, Bax JJ (2016) Noninvasive imaging markers associated with sudden cardiac death. Trends Cardiovasc Med 26(4):348–360
Green JJ, Berger JS, Kramer CM, Salerno M (2012) Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 5(4):370–377
Adabag AS, Maron BJ, Appelbaum E et al (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51(14):1369–1374
Kwon DH, Setser RM, Popović ZB et al (2008) Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging 24(6):617–625
Rubinshtein R, Glockner JF, Ommen SR et al (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3(1):51–58
Inada K, Seiler J, Roberts-Thomson KC et al (2011) Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 22(1):41–48
Weng Z, Yao J, Chan RH et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 9(12):1392–1402
Amano Y, Yanagisawa F, Kitamura M et al (2017) Relationship of nonseptal late gadolinium enhancement to ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Comput Assist Tomogr 41(5):768–771. https://doi.org/10.1097/RCT.0000000000000599
Ismail TF, Jabbour A, Gulati A et al (2014) Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 100(23):1851–1858
Chan RH, Maron BJ, Olivotto I et al (2015) Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol 116(3):436–441
Sakamoto N, Kawamura Y, Sato N et al (2015) Late gadolinium enhancement on cardiac magnetic resonance represents the depolarizing and repolarizing electrically damaged foci causing malignant ventricular arrhythmia in hypertrophic cardiomyopathy. Heart Rhythm 12(6):1276–1284
Hinojar R, Zamorano JL, Gonzalez Gómez A et al (2017) ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients. Clin Cardiol 40(10):853–860. https://doi.org/10.1002/clc.22735. Epub 2017 Jun 14
Doesch C, Tülümen E, Akin I et al (2017) Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy. Sci Rep 7(1):6336
Stroumpoulis KI, Pantazopoulos IN, Xanthos TT (2010) Hypertrophic cardiomyopathy and sudden cardiac death. World J Cardiol 2(9):289–298
Olivotto I, Maron BJ, Appelbaum E et al (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106(2):261–267
Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495
Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):875–887
O’Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):867–874
Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40(12):2156–2164
Berliner JI, Kino A, Carr JC et al (2013) Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 29(1):191–197
Choudhury L, Rigolin VH, Bonow RO (2017) Integrated imaging in hypertrophic cardiomyopathy. Am J Cardiol 119(2):328–339
Maron MS, Finley JJ, Bos JM et al (2008) Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 118(15):1541–1549
Hanneman K, Crean AM, Williams L et al (2014) Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy. J Thorac Imaging 29(6):331–339
Sakamoto T, Tei C, Murayama M et al (1976) Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J 17(5):611–629
Trojan MKB, Biederman RW (2017) Management of an asymptomatic patient with the apical variant of hypertrophic cardiomyopathy. Echocardiography 34(7):1092–1095
Harris KM, Spirito P, Maron MS et al (2006) Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114(3):216–225
Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287(10):1308–1320
Frey N, Luedde M, Katus HA (2011) Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 9(2):91–100
Ho CY (2012) Hypertrophic cardiomyopathy in 2012. Circulation 125(11):1432–1438
Maron BJ, Maron MS, Semsarian C (2012) Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 9(1):57–63
Wang J, Wang Y, Zou Y et al (2014) Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail 16(9):950–957
Chida A, Inai K, Sato H et al (2017) Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. Heart Vessels 32(6):700–707
Ingles J, Doolan A, Chiu C (2005) Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 42(10):e59
Guo X, Fan C, Wang Y et al (2017) Genetic anticipation in a special form of hypertrophic cardiomyopathy with sudden cardiac death in a family with 74 members across 5 generations. Medicine (Baltimore) 96(11):e6249
Fraiche A, Hypertrophic Cardiomyopathy WA (2016) New evidence since the 2011 American Cardiology of Cardiology Foundation and American Heart Association guideline. Curr Cardiol Rep 18(8):70
Maron BJ, Mathenge R, Casey SA et al (1999) Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 33(6):1590–1595
Zou Y, Song L, Wang Z et al (2004) Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 116(1):14–18
Maron BJ, Spirito P, Roman MJ et al (2004) Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am J Cardiol 93(12):1510–1514
Maro EE, Janabi M, Kaushik R (2006) Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. Trop Doct 36(4):225–227
Ng CT, Chee TS, Ling LF et al (2011) Prevalence of hypertrophic cardiomyopathy on an electrocardiogram-based pre-participation screening programme in a young male South-East Asian population: results from the Singapore Armed Forces Electrocardiogram and Echocardiogram screening protocol. Europace 13(6):883–888
Lipshultz SE, Sleeper LA, Towbin JA et al (2003) The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348(17):1647–1655
Nugent AW, Daubeney PEF, Chondros P et al (2005) Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 112(9):1332–1338
Olivotto I, Girolami F, Sciagrà R et al (2011) Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 58(8):839–848
Watkins H, McKenna WJ, Thierfelder L et al (1995) Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332(16):1058–1064
Van Driest SL, Maron BJ, Ackerman MJ (2004) From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy. Heart 90(1):7–8
O’Mahony C, Tome-Esteban M, Lambiase PD et al (2013) A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart 99(8):534–541
Efthimiadis GK, Parcharidou DG, Giannakoulas G et al (2009) Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 104(5):695–699
Olivotto I, Cecchi F, Poggesi C, Yacoub MH (2012) Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 5(4):535–546
Maron BJ, Casey SA, Chan RH et al (2015) Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol 116(5):757–764
Zhu SH, Li Y, Huang W et al (2017) Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients. Zhonghua Xin Xue Guan Bing Za Zhi 45(5):404–408
Fernández A, Quiroga A, Ochoa JP et al (2016) Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a Reference Center in South America. Am J Cardiol 118(1):121–126
Vriesendorp PA, Schinkel AFL, Liebregts M et al (2015) Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 8(4):829–835
Elliott PM, Gimeno Blanes JR, Mahon NG et al (2001) Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357(9254):420–424
Vriesendorp PA, Schinkel AFL, Van Cleemput J et al (2013) Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J 166(3):496–502
Girolami F, Ho CY, Semsarian C et al (2010) Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 55(14):1444–1453
Ommen SR, Maron BJ, Olivotto I et al (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):470–476
ten Cate FJ, Soliman OII, Michels M et al (2010) Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 3(3):362–369
Veselka J, Tomašov P, Zemánek D (2011) Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol 27(6):763–767
Jensen MK, Prinz C, Horstkotte D et al (2013) Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 99(14):1012–1017
Sugrue A, Killu AM, DeSimone CV et al (2017) Utility of T‑wave amplitude as a non-invasive risk marker of sudden cardiac death in hypertrophic cardiomyopathy. Open Heart 4(1):e561
Akboğa MK, Gülcihan Balcı K, Yılmaz S et al (2017) Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. Anatol J Cardiol 18(1):48–53
Castro-Torres Y (2017) Tp-e interval and Tp-e/QTc ratio: new choices for risk stratification of arrhythmic events in patients with hypertrophic cardiomyopathy. Anatol J Cardiol 17(6):493
Castro-Torres Y, Carmona-Puerta R, Katholi RE (2015) Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 3(8):705–720
Gupta P, Patel C, Patel H et al (2008) T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 41(6):567–574
Saumarez RC, Pytkowski M, Sterlinski M et al (2008) Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 29(13):1653–1661
Magrì D, Santolamazza C (2017) Cardiopulmonary exercise test in hypertrophic cardiomyopathy. Ann Am Thorac Soc 14(Supplement_1):S102–S109
Finocchiaro G, Haddad F, Knowles JW et al (2015) Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. JACC Heart Fail 3(5):408–418
Belardinelli R, Lacalaprice F, Carle F et al (2003) Exercise-induced myocardial ischaemia detected by cardiopulmonary exercise testing. Eur Heart J 24(14):1304–1313
Masri A, Pierson LM, Smedira NG et al (2015) Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J 169(5):684–692.e1
Coats CJ, Rantell K, Bartnik A et al (2015) Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circ Heart Fail 8(6):1022–1031
Magrì D, Limongelli G, Re F et al (2016) Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart 102(8):602–609
Brito D (2017) Predicting risk of sudden death in hypertrophic cardiomyopathy: can additional simple markers help? Rev Port Cardiol 36(4):247–249
Cambronero F, Marín F, Roldán V et al (2009) Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 30(2):139–151
EXpert Group on Biomarkers (2014) Biomarkers in cardiology—part 1—in heart failure and specific cardiomyopathies. Arq Bras Cardiol 103(6):451–459
Brito D, Matias JS, Sargento L et al (2004) Plasma N‑terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 23(12):1557–1582
Ozyilmaz S, Akgul O, Uyarel H et al (2017) The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy. Rev Port Cardiol 36(4):239–246
Colan SD, Lipshultz SE, Lowe AM et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 115(6):773–781
Maron BJ, Spirito P, Ackerman MJ, et al (2013) Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 61(14):1527–1535
Decker JA, Rossano JW, Smith EO et al (2009) Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 54(3):250–254
Ostman-Smith I, Wettrell G, Keeton B et al (2005) Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young 15(6):632–642
Dewland TA, Pellegrini CN, Wang Y et al (2011) Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol 58(10):1007–1013
Norrish G, Cantarutti N, Pissaridou E et al (2017) Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis. Eur J Prev Cardiol 24(11):1220–1230
Schinkel AFL, Vriesendorp PA, Sijbrands EJG et al (2012) Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail 5(5):552–559
Konstantinou DM, Efthimiadis GK, Vassilikos V et al (2016) Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Med 17(6):433–439
Wilkoff BL, Fauchier L, Stiles MK et al (2016) 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm 13(2):e50–e86
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
S. Marrakchi, I. Kammoun, E. Bennour, L. Laroussi and S. Kachboura declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Marrakchi, S., Kammoun, I., Bennour, E. et al. Risk stratification in hypertrophic cardiomyopathy. Herz 45, 50–64 (2020). https://doi.org/10.1007/s00059-018-4700-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00059-018-4700-8